Cargando…
P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171703/ http://dx.doi.org/10.1097/01.HS9.0000936164.84357.ed |
| _version_ | 1785039479609753600 |
|---|---|
| author | Weisel, K. Kumar, S. Moreau, P. Bahlis, N. Facon, T. Plesner, T. Orlowski, R. Basu, S. Nahi, H. Hulin, C. Quach, H. Goldschmidt, H. O’Dwyer, M. Perrot, A. Venner, C. Raje, N. Tiab1, M. Macro, M. Frenzel, L. Leleu, X. Pei, H. Krevvata, M Carson, R Borgsten, F. Usmani, S. |
| author_facet | Weisel, K. Kumar, S. Moreau, P. Bahlis, N. Facon, T. Plesner, T. Orlowski, R. Basu, S. Nahi, H. Hulin, C. Quach, H. Goldschmidt, H. O’Dwyer, M. Perrot, A. Venner, C. Raje, N. Tiab1, M. Macro, M. Frenzel, L. Leleu, X. Pei, H. Krevvata, M Carson, R Borgsten, F. Usmani, S. |
| author_sort | Weisel, K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171703 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101717032023-05-11 P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY Weisel, K. Kumar, S. Moreau, P. Bahlis, N. Facon, T. Plesner, T. Orlowski, R. Basu, S. Nahi, H. Hulin, C. Quach, H. Goldschmidt, H. O’Dwyer, M. Perrot, A. Venner, C. Raje, N. Tiab1, M. Macro, M. Frenzel, L. Leleu, X. Pei, H. Krevvata, M Carson, R Borgsten, F. Usmani, S. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171703/ http://dx.doi.org/10.1097/01.HS9.0000936164.84357.ed Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Weisel, K. Kumar, S. Moreau, P. Bahlis, N. Facon, T. Plesner, T. Orlowski, R. Basu, S. Nahi, H. Hulin, C. Quach, H. Goldschmidt, H. O’Dwyer, M. Perrot, A. Venner, C. Raje, N. Tiab1, M. Macro, M. Frenzel, L. Leleu, X. Pei, H. Krevvata, M Carson, R Borgsten, F. Usmani, S. P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title | P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_full | P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_fullStr | P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_full_unstemmed | P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_short | P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_sort | p09 daratumumab plus lenalidomide and dexamethasone (d-rd) versus lenalidomide and dexamethasone (rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (ndmm): updated analysis of the phase 3 maia study |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171703/ http://dx.doi.org/10.1097/01.HS9.0000936164.84357.ed |
| work_keys_str_mv | AT weiselk p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT kumars p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT moreaup p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT bahlisn p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT facont p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT plesnert p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT orlowskir p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT basus p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT nahih p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT hulinc p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT quachh p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT goldschmidth p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT odwyerm p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT perrota p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT vennerc p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT rajen p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT tiab1m p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT macrom p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT frenzell p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT leleux p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT peih p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT krevvatam p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT carsonr p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT borgstenf p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy AT usmanis p09daratumumabpluslenalidomideanddexamethasonedrdversuslenalidomideanddexamethasonerdaloneintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomandmmupdatedanalysisofthephase3maiastudy |